7 results about "Nicotinamide riboside" patented technology

A stable intravenous (IV) composition comprises, in the intravenous form, nicotinamide riboside (NR) as described, or another nicotinyl riboside compound that is an NAD+ precursor. NR chloride may be provided in an intravenous (IV) formulation for administration to human subjects.

The present application relates to the field of biotechnology, in particular to a catalytic enzyme for high-yield nicotinamide mononucleotide and application, and provides a mutant of nicotinamide riboside kinase, wherein the wild type is derived from a flying fox and has mutation sites G87A / E91P / D109Y, and the heat-stable nicotinamide riboside kinase NRK03-G87A / E91P / D109Y of the present application can withstand 50 DEG C heat shock, and is suitable for completing a catalytic reaction of 600 mM high substrate concentration at 45 DEG C, and the reported highest yield of NMN is 184 g / L, thereby reducing the manufacturing cost in the production process.

The application belongs to the technical field of medicine, and particularly relates to a blood vessel targeting anti-aging oral composition and application thereof. In view of problems such as endothelial dysfunction, matrix sclerosis and accumulation of senescent cells caused by vascular aging, the composition comprises active ingredients: beetroot extract, fisetin, salvianolic acid B, panax notoginseng total saponins, cocoa flavanol, pterostilbene, procyanidin B2, luteolin, nicotinamide riboside and astaxanthin. The composition is prepared by a process of adsorbing astaxanthin on beetroot extract, mixing other active ingredients, fillers and glidants after fisetin and salvianolic acid B are prepared into a solid dispersion, and sequentially cooperating each module, so that the pulse wave transmission velocity can be significantly reduced and the skeletal muscle capillary density can be increased, and the composition is mainly used for preparing a medicine for improving vascular stiffness, promoting microcirculation and removing vascular senescent cells.

The application discloses a nicotinamide nucleoside rapid cooling crystallization device, and relates to the technical field of crystallization equipment for biological medicine intermediates. The device comprises a crystallization kettle, the outer surface of the crystallization kettle is provided with a spiral flow guide jacket, the bottom of the spiral flow guide jacket is provided with a nitrogen inlet pipe for conveying liquid nitrogen refrigerant into the jacket. Each circle of the spiral flow guide jacket is provided with an isolation seat, an adjusting cylinder is rotatably installed on the inner side of the isolation seat, the surface of the adjusting cylinder is provided with a through hole and a flow interception hole, and the flow direction of the liquid nitrogen in the single-circle spiral flow guide jacket is switched through the rotation of the adjusting cylinder. The outer side of the crystallization kettle is provided with a nitrogen collecting pipe, the adjusting cylinder is communicated with the nitrogen collecting pipe through an eccentric hole structure, and the cut-off liquid nitrogen is discharged. Through the above structure, the spiral rising range of the liquid nitrogen can be selectively controlled according to the liquid level height of the raw material in the crystallization kettle, so that the liquid nitrogen only cools the corresponding crystallization area, the invalid cooling of the area above the liquid level is avoided, and the consumption of the cold source is reduced.

The purpose of the present invention is to provide a composition having the effect of increasing NAD concentration. The present invention pertains to a composition containing, as active ingredients: at least one selected from the group consisting of nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and salts thereof; and at least one type of sesamin or the like.

This invention discloses a purine nucleoside phosphorylase mutant and its application in the preparation of nicotinamide ribomatate. The PNP mutant is a substitution of at least one amino acid residue from the wild-type PNPLf derived from *Leptodactylus fuscus*, specifically serine at position 244, threonine at position 247, and alanine at position 290, preferably the S244Y / T247W / A290F triple mutant. This invention also provides a one-pot enzymatic method for preparing NR malate, using inosine and nicotinamide as substrates. The PNP mutant catalyzes a phosphorylation-transglycosylation tandem reaction to generate NR, which is then reacted with malic acid in situ to form NR malate. The NR yield can reach over 92%, and the total yield of NR malate can reach over 82%. This method is green, efficient, highly selective, and simplified, avoiding the large-scale use of organic solvents, making it suitable for industrial production.